Last reviewed · How we verify
ST-246 Days 1 - 3
At a glance
| Generic name | ST-246 Days 1 - 3 |
|---|---|
| Also known as | Tecovirimat |
| Sponsor | SIGA Technologies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tecovirimat for Treatment of Monkeypox Virus (PHASE2)
- Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
- Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS (PHASE2)
- Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days (PHASE3)
- Phase I Trial of an Investigational Small Pox Medication (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ST-246 Days 1 - 3 CI brief — competitive landscape report
- ST-246 Days 1 - 3 updates RSS · CI watch RSS
- SIGA Technologies portfolio CI